Skip to main content
. 2022 Oct 14;12:1023391. doi: 10.3389/fonc.2022.1023391

Figure 3.

Figure 3

The killing assay of pirarubicin by the CellTiter-Glo and CCK8 assays. (A–G) The CellTiter-Glo assay to measure the IC50 value of pirarubicin in the primary breast cancer cells BC3, BC4, BC5, BC6, BC10, and BC13. (H–N) The CCK8 assay to measure the IC50 value of pirarubicin in the primary breast cancer cells BC3, BC4, BC5, BC6, BC10, and BC13.